Selective modification of fluciclovine (F-18) transport in prostate carcinoma xenografts

• Type of Material: Article
• Authors: Funmilayo Tade, Emory University; W. G. Wiles, Winship Cancer Institute; G. Lu, Stanford University; Birdal Bilir, Emory University; Oladunni Akin-Akintayo, Emory University; J. S. Lee, Emory University; D. Patil, Winship Cancer Institute; Weiping Yu, Emory University; C. Ormenisan Gherasim, Emory University; Baowei Fei, Emory University; Carlos Moreno, Emory University; Adeboye Osunkoya, Emory University; E. J. Teoh, University of Oxford; S. Oka, Nihon Mediphys Co., Ltd; H. Okudaira, Nihon Mediphys Co., Ltd; Mark Goodman, Emory University; David Schuster, Emory University
• Language: English
• Date: 2018-09-01
• Publisher: Springer Wien
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © Springer-Verlag GmbH Austria, part of Springer Nature 2018
• Final Published Version (URL): http://dx.doi.org/10.1007/s00726-018-2600-0
• Title of Journal or Parent Work: Amino Acids
• Volume: 50
• Issue: 9
• Start Page: 1301
• End Page: 1305
• Grant/Funding Information: Research reported in this publication was supported in part by the Cancer Animal Models Shared Resource, a core supported by the Winship Cancer Institute of Emory University and Cancer Center Support Grant P30 CA138292.; This study was otherwise internally funded.
• Keywords: Amino acid transport; Axumin; Biochemistry & Molecular Biology; Life Sciences & Biomedicine; Fluciclovine; Mechanisms; Amino acid transporters; PET/CT; Science & Technology; PC3; Cancer cells; ASCT2; Prostate cancer; Expression
• Research Categories: Biology, Cell; Chemistry, Biochemistry; Health Sciences, Oncology; Biology, Molecular

Abstract

We investigated if previously demonstrated inhibition of fluciclovine (18F) in vitro could be replicated in a PC3-Luc xenograft mouse model. Following intratumoral injection of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), alpha-(methylamino)isobutyric acid (MeAIB) or saline, fluciclovine PET tumor-to-background activity was 43.6 (± 5.4)% and 25.3 (± 5.2)% lower in BCH (n = 6) and MeAIB (n = 5) injected PC3 Luc xenografts, respectively, compared to saline-injected controls (n = 2). Partial inhibition of fluciclovine uptake by BCH and MeAIB can be demonstrated in vivo similar to previous in vitro modeling.